Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nerdwallet Inc (NRDS) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

NRDS trades at $9.47, down 1.56% today, with a bullish technical signal from moving averages and strong fundamentals including a 93% gross margin and three consecutive earnings beats. Revenue grew to $837M in 2025, with net income reaching $49M. Analyst consensus is Buy with a $12.75 target, implying 35% upside. Positive news highlights the company's pivot to higher-margin transactions and launch of a Financial Resilience Index.

The outlook is positive given undervaluation (P/E 10.18, P/S 0.83) and earnings momentum, but risks include search traffic dependence and projected negative cash flow in 2026. Institutional sentiment is bullish with 66% Buy ratings, supporting a constructive view for long-term investors seeking growth at a reasonable price.